Generating a high-quality monoclonal stable cell line with stable genetic modifications is essential for studying targets in drug discovery, whether they are GPCRs, ion channels, or kinases. Variable gene expression can lead to non-repeatable results and reduce confidence in downstream screening decisions.
ICE Bioscience combines plasmid, lentiviral, and CRISPR-based approaches to build custom cellular tools for drug discovery. From gene delivery and genome editing through clone screening and functional characterization, our cell engineering platform is designed to provide fit-for-purpose models for target validation, hit identification, and downstream pharmacology studies.
Each program begins with the intended biological question and downstream assay endpoint. Host-cell selection, expression strategy, editing design, clone screening, and validation readouts are aligned to support the required pharmacology rather than simply generate an expressing cell population.
The development path is configured according to the target, host-cell context, intended modification, and functional endpoint. Project-specific screening and quality criteria are agreed during study design.
Constitutive and inducible expression systems can be selected according to the target biology and project requirements.
Lentiviral systems support efficient stable integration and can be applied to cells that are difficult to transfect using conventional approaches.
CRISPR/Cas9 approaches support knock-in, knock-out, gene mutation, and gene knockdown strategies for precise genomic modification.
The most useful clone is not necessarily the clone with the highest expression. Screening is configured to identify models with the expression profile, cellular health, assay window, and pharmacological response required for the intended study.
| Validation Area | Relevant Readout | Decision Supported |
|---|---|---|
| Clone selection efficiency | High-content cell imaging and fluorescence-activated cell sorting (FACS) | Selection and enrichment of appropriate cell populations |
| Target expression | Project-appropriate expression and localization assessment | Confirmation that the engineered target is suitable for the intended assay |
| Functional performance | Target-specific cellular or biochemical assay readouts | Identification of clones with relevant biological and pharmacological responses |
| Reproducibility planning | Project-defined cell banking and quality criteria | Preparation of fit-for-purpose materials for downstream studies |
A diverse range of host cells can be selected to support appropriate overexpression or repressed expression of the target gene and the intended drug screening assay.
GeCKO v2.0 library screening supports genome-scale CRISPR knock-out studies and can be paired with custom sgRNA library design for tailored research questions.
Share your target, desired genetic modification, host-cell preference, and downstream assay objective to begin planning a fit-for-purpose cell engineering strategy.
We value your inquiries and are here to provide you with tailored solutions for your drug discovery and development needs. Whether you have questions, require more information, or are interested in discussing potential collaborations, our team of experts is just a message away.
Feel free to reach out to us.
Address: Bldg 16, Yd 18, Kechuang 13th St, Etown, Tongzhou Dist, Beijing, 100176, China
Email: marketing@ice-biosci.com
Tel：+86-10-67809840
Get a quote
Go top
